Tim Boreham interviews Anatara CEO Steven Lydeamore for Dr Boreham's Crucible

Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.

Steve spoke with Tim about the Company's evolving story into the human health space, the growing concern around the use of antibiotics in agriculture and the opportunity a product like Detach presents. The discussion also covered how the Company is setting itself up to play in the expansive market for over-the-counter gastrointestinal and digestive products with its Gastrointestinal ReProgramming (GaRP) dietary supplement "a three pronged approach to bug busting".

Dr Boreham's Crucible: Anatara Lifesciences can be read here.
https://anataralifesciences.com/media-centre/media-coverage/


About Anatara Lifesciences Limited

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

    

Related Companies

Anatara Lifesciences Limited